Shanghai Pharmaceuticals Holding (2607) Fundamentals 2026 — P/E 10.7x, Revenue Analysis | SniperIQ
Shanghai Pharmaceuticals Holding (2607) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of HK$69.0B, trading at HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai Pharmaceuticals Holding's market cap?
Shanghai Pharmaceuticals Holding (2607) has a market capitalization of approximately HK$69.0B, trading at HK
What is Shanghai Pharmaceuticals Holding's P/E ratio?
Shanghai Pharmaceuticals Holding's trailing twelve-month P/E ratio is 10.7x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai Pharmaceuticals Holding?
Shanghai Pharmaceuticals Holding runs a net profit margin of 2.0%, a gross margin of 10.8%, and an operating margin of 3.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai Pharmaceuticals Holding generate?
Shanghai Pharmaceuticals Holding reported revenue of ¥283.6B for fiscal year 2025, with net income of ¥5.7B and earnings per share (EPS) of 1.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai Pharmaceuticals Holding pay a dividend?
Shanghai Pharmaceuticals Holding offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai Pharmaceuticals Holding financially healthy?
Shanghai Pharmaceuticals Holding carries a debt-to-equity ratio of 0.81x and a current ratio of 1.34x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai Pharmaceuticals Holding a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Pharmaceuticals Holding (2607) the key facts are: market cap HK$69.0B, P/E 10.7x, revenue ¥283.6B, 52-week range 10.96-13.12. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai Pharmaceuticals Holding's full fundamentals live
Get Shanghai Pharmaceuticals Holding's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.